Areca-arecoline derivative containing amino acid fragment as well as preparation method and application of arecoline derivative
By designing arecaine derivatives containing amino acid fragments, the stability and volatile nature of arecaine in pesticide applications are solved, effective inhibition of plant pathogens is achieved, and environmentally friendly agricultural fungicide solutions are provided.
Patent Information
- Application Number
- CN202411040293.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-07-31
AI Technical Summary
In the prior art, the natural product arecaine has problems with stability and volatile in pesticide applications, which are difficult to be directly used for pesticide development, and existing antibacterial drugs have problems with insufficient resistance and environmental friendliness.
A series of arecane derivatives containing amino acid fragments were designed, and synthesized through the principle of bioelectronic isobaric and active group splicing, and their preparation methods and applications are provided for the preparation of agricultural fungicides.
It significantly enhances the antibacterial activity of plant pathogens, provides an environmentally friendly, low-residue agricultural fungicide solution, suitable for the prevention and treatment of a variety of plant pathogenic diseases.
Smart Images

Figure CN118978477A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of chemical pesticide synthesis, and specifically relates to an arecoline derivative containing an amino acid fragment and a preparation method, and application of the arecoline derivative containing an amino acid fragment as an agricultural fungicide. Background Art
[0002] Natural products are diverse in nature, have good biocompatibility, unique mechanisms of action and are easy to degrade, and are widely used in drug development. Alkaloids are an important component of natural products, but their complex chemical structure, instability in nature and volatility make them difficult to apply directly in practice. Using natural products as lead compounds for modification is a hot topic in pesticide development, with many successful development cases. For example, neonicotinoid insecticides such as imidacloprid were developed using nicotine in tobacco as the lead compound, and carbamate fungicides such as demecarb were developed using physostigmine as the lead compound.
[0003] Areca nut is a traditional southern medicinal plant. Arecoline, as a representative alkaloid in betel nut, has rich biological activities. Research focuses on the nervous system, treatment of cardiovascular diseases, killing (repelling) insects and anti-pathogenic microorganisms. Studies have shown that in terms of antibacterial activity, arecoline has inhibitory effects on Staphylococcus aureus, Bacillus subtilis, Bacillus cereus, and Escherichia coli. The minimum inhibitory concentrations for Staphylococcus aureus and Bacillus subtilis are 12.50 and 6.25 mg / mL, respectively, and the minimum inhibitory concentrations for Bacillus cereus and Escherichia coli are both 25.00 mg / mL; in terms of insecticidal (repellent) activity, arecoline can play a similar function to acetylcholine, affecting the nervous system of liver flukes and Schistosoma mansoni, thereby paralyzing the worms and causing their death. It has a killing effect on pork ascaris, echinococcus and snails. In addition, arecoline also has insecticidal activity against cattle ticks, golden apple snails and diamondback moth larvae. The LC of the drug treatment for 24 hours is 50 They are 4.16mg / L, 5.64mg / L and 70.28mg / L respectively.
[0004] As antimicrobial compounds, small molecule peptide derivatives such as amino acids have the advantages of high safety, good antimicrobial activity, broad antimicrobial spectrum, and low resistance to drug resistance. In addition, their easy degradation, low residue and environmentally friendly characteristics give them unique advantages in the design of antimicrobial drugs. Amino acid small molecules are widely used as active fragments in pesticide structures. Commercial pesticides such as valerian, valerian, benzathiapyr and fluvalinate all contain amino acid structural fragments. Summary of the invention
[0005] In response to the above technical problems in the related art, the present invention utilizes the principles of bioisostere and active group splicing to design and synthesize a series of arecoline derivatives containing amino acid fragments, and provides their preparation methods and applications, which can solve the above problems.
[0006] To achieve the above technical objectives, the technical solution of the present invention is implemented as follows:
[0007] An arecoline derivative containing an amino acid fragment, the general structural formula of which is formula (1):
[0008]
[0009] The X group represents O or NH; the value of n is 0, 1, 2 or 3.
[0010] Furthermore, in the structural formula (I) of an arecoline derivative containing an amino acid fragment, R 1 Selected from hydrogen atom, methyl, ethyl, cyclopropyl, isopropyl and tert-butyl.
[0011] Furthermore, in the structural formula (I) of an arecoline derivative containing an amino acid fragment, R 2 Selected from hydrogen atom, methyl, isopropyl, isobutyl, sec-butyl, benzyl and CH3SCH2CH2.
[0012] Furthermore, in the structural formula (I) of an arecoline derivative containing an amino acid fragment, R 3 is selected from aryl, aliphatic heterocycle, oxygen heterocycle, nitrogen heterocycle, sulfur heterocycle, aromatic heterocycle, benzoheterocycle, or condensed ring with a substituent, wherein R 3 The substituents are halogen atoms such as fluorine, chlorine and bromine, and mono- or poly-substituted groups such as methyl, isopropyl, tert-butyl, methoxy, nitro, cyano, trifluoromethoxy and trifluoromethyl.
[0013] Furthermore, a method for preparing an arecoline derivative containing an amino acid fragment is obtained by the following steps:
[0014]
[0015] Furthermore, any of the above described arecoline derivatives containing amino acid fragments are used as agricultural fungicides.
[0016] Furthermore, the agricultural fungicide is prepared into a preparation and a composition as an agricultural fungicide original drug, and the agricultural fungicide contains at least one of the above-mentioned arecoline derivatives containing amino acid fragments.
[0017] Furthermore, the dosage form of the agricultural fungicide is at least one of emulsifiable concentrate, water emulsion, microemulsion, wettable powder, water dispersible granules, suspension or other suitable dosage forms.
[0018] Furthermore, the content of the arecoline derivative containing the amino acid fragment in the fungicide composition prepared from the agricultural fungicide is 1-99.9% by weight.
[0019] Furthermore, the use of the arecoline derivative or combination preparation containing an amino acid fragment as an agricultural fungicide is characterized in that the agricultural fungicide is used to prevent and control plant pathogenic diseases; wherein the plant pathogens are the pathogens including: Oomycetes, such as downy mildew, white rust, damping-off, cotton rot, phytophthora, and late blight; Basidiomycetes, such as stripe rust, smut, and sheath blight; Ascomycetes, such as powdery mildew, sclerotinia, black spot, and fusarium; Deuteromycetes, such as wilt, root rot, damping-off, anthracnose, verticillium wilt, gray mold, brown spot, black spot, black rot, stem rot, spot blight, early blight, ring rot, leaf blight, and phomopsis.
[0020] Beneficial effects:
[0021] The arecoline derivatives containing amino acid fragments provided by the present invention have a novel molecular structure, and compared with the lead compound arecoline, the antibacterial activity is significantly enhanced, and the derivatives have a good inhibitory effect on plant pathogens such as rice blast fungus, pitaya black spot fungus, mango stem rot fungus, wheat stem base rot fungus, banana anthracnose fungus, rice sheath blight fungus, apple ring rot fungus, rapeseed sclerotinia fungus and pepper phytophthora fungus, and can be used for the development and use of effective ingredients for preparing agricultural fungicides or adjuvants. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0023] The present invention is further described in detail below with reference to the accompanying drawings.
[0024] Figure 1 is the general structural formula of an arecoline derivative containing an amino acid fragment of the present invention;
[0025] Figure 2a This is a table showing the structures of some compounds (Ⅰ-1 to Ⅰ-22) after the general structure of an arecoline derivative containing an amino acid fragment of the present invention is replaced by a substituent;
[0026] Figure 2bThis is a structural description table of some compounds (Ⅰ-23 to Ⅰ-54) after the general structural formula of an arecoline derivative containing an amino acid fragment of the present invention is replaced by a substituent;
[0027] Figure 2c This is a table showing the structures of some compounds (Ⅰ-55 to Ⅰ-86) after the general structure of an arecoline derivative containing an amino acid fragment of the present invention is replaced by a substituent;
[0028] Figure 2d This is a structural description table of some compounds (Ⅰ-87 to Ⅰ-106) after the general structural formula of an arecoline derivative containing an amino acid fragment of the present invention is replaced by a substituent;
[0029] Figure 3a This is a table of antibacterial activity test results (100 mg / L) of some compounds (Ⅰ-1 to Ⅰ-6) after the arecoline derivatives containing amino acid fragments of the present invention are replaced by substituents;
[0030] Figure 3b This is a table of antibacterial activity test results (100 mg / L) of some compounds (Ⅰ-6 to Ⅰ-34) after the arecoline derivatives containing amino acid fragments of the present invention are replaced by substituents;
[0031] Figure 3c This is a table of antibacterial activity test results (100 mg / L) of some compounds (Ⅰ-35 to Ⅰ-62) after the arecoline derivatives containing amino acid fragments of the present invention are replaced by substituents;
[0032] Figure 3d This is a table of antibacterial activity test results (100 mg / L) of some compounds (Ⅰ-63 to Ⅰ-91) after the arecoline derivatives containing amino acid fragments of the present invention were replaced by substituents;
[0033] Figure 3e This is a table of antibacterial activity test results (100 mg / L) of some compounds (Ⅰ-92 to Ⅰ-106) after the arecoline derivatives containing amino acid fragments of the present invention were replaced by substituents;
[0034] Figure 3f This is the antibacterial activity test result table of arecoline, thiophanate-methyl and prochloraz (100 mg / L). DETAILED DESCRIPTION
[0035] In order to enable those skilled in the art to better understand the technical solution of the present invention, the technical solution of the arecoline derivative containing amino acid fragments and its preparation method and application of the present invention will be further explained below in conjunction with the drawings and specific implementation methods.
[0036] An arecoline derivative containing an amino acid fragment, the general structural formula of which is formula (1):
[0037]
[0038] wherein the X group represents O or NH; the value of n is 0, 1, 2 or 3;
[0039] In the structural formula (I) of the above-mentioned arecoline derivative containing an amino acid fragment, R 1 Selected from hydrogen atom, methyl, ethyl, cyclopropyl, isopropyl and tert-butyl.
[0040] In the structural formula (I) of the above-mentioned arecoline derivative containing an amino acid fragment, R 2 Selected from hydrogen atom, methyl, isopropyl, isobutyl, sec-butyl, benzyl and CH3SCH2CH2.
[0041] In the structural formula (I) of the above-mentioned arecoline derivative containing an amino acid fragment, R 3 is selected from aryl, aliphatic heterocycle, oxygen heterocycle, nitrogen heterocycle, sulfur heterocycle, aromatic heterocycle, benzoheterocycle, or condensed ring with a substituent, wherein R 3 The substituents are halogen atoms such as fluorine, chlorine and bromine, and mono- or poly-substituted groups such as methyl, isopropyl, tert-butyl, methoxy, nitro, cyano, trifluoromethoxy and trifluoromethyl.
[0042] The method for preparing the above-mentioned arecoline derivative containing an amino acid fragment comprises the following steps:
[0043]
[0044] The reaction is:
[0045] The above-mentioned preparation method uses trifluoroacetic acid for deprotection under ice bath conditions, and other reactions can be carried out at room temperature, and post-treatment can be carried out according to conventional methods.
[0046] Application of the arecoline derivative containing amino acid fragments described in any one of the above as an agricultural fungicide.
[0047] The specific preparation method of the compound of the present invention is described below by way of examples:
[0048] Example 1
[0049] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-11):
[0050]
[0051] Its synthesis method is:
[0052] 2-Fluorobenzyl alcohol (1.2mmol, 151mg), BOC-Val-OH (1.5mmol, 325mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane were added to a round-bottom flask and stirred evenly, and then EDCI (1.5mmol, 285mg) was added. The reaction was stirred at room temperature for 3h, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in turn, and dried over anhydrous sodium sulfate. Filtered and concentrated under reduced pressure to obtain intermediate 2, which was directly used in subsequent reactions without purification.
[0053] The intermediate 2 was transferred to a 25 mL round-bottom flask, and 4 mL of dichloromethane was added and placed in an ice bath. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel. After reacting for 2 h, the pH was adjusted to a weak alkaline (8-9) using saturated sodium carbonate. The mixed solution was extracted with dichloromethane (×20), the organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a colorless oily liquid or a white solid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30 mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in sequence, and dried over anhydrous sodium sulfate. The residue was filtered off, concentrated under reduced pressure, and separated by column chromatography (eluent: DCM / MeOH=15 / 1) to obtain compound I-1.
[0054] Compound H NMR spectrum, 1 H NMR(400MHz, CDCl3)δ0.87(d,J=6.86Hz,6H),2.12–2.22(m,1H),2.29–2.35(m,2H),2.38(s,3H),2.43–2.55(m,2H),3.06–3.23(m,2H) ),4.65(dd,J=4.77,8.69Hz,1H),5.13–5.30(m,2H),6.17(d,J=8.70Hz,1H),6.50–6.59(m,1H),6.99–7.16(m,2H),7.28–7.41(m,2H).
[0055] Example 2
[0056] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-13):
[0057]
[0058] Its synthesis method is:
[0059] 2-Chloro-5-hydroxymethylpyridine (1.2mmol, 172mg), BOC-Val-OH (1.5mmol, 325mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane were added to a round-bottom flask and stirred evenly, and then EDCI (1.5mmol, 285mg) was added. The reaction was stirred at room temperature for 3h, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in turn, and dried over anhydrous sodium sulfate. Filtered and concentrated under reduced pressure to obtain intermediate 2, which was directly used in subsequent reactions without purification.
[0060] The intermediate 2 was transferred to a 25 mL round-bottom flask, and 4 mL of dichloromethane was added and placed in an ice bath. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel. After reacting for 2 h, the pH was adjusted to a weak alkaline (8-9) using saturated sodium carbonate. The mixed solution was extracted with dichloromethane (×20), the organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a colorless oily liquid or a white solid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30 mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in sequence, and dried over anhydrous sodium sulfate. The residue was filtered off, concentrated under reduced pressure, and separated by column chromatography (eluent: DCM / MeOH=15 / 1) to obtain compound I-13.
[0061] Compound I-13 H NMR spectrum, 1 H NMR(400MHz, CDCl3)δ0.87(d,J=6.90Hz,3H),0.91(d,J=6.85Hz,3H),2.16(pd,J=5.02, 6.85Hz,1H),2.30–2.37(m,2H),2.39(s,3H),2.50(td,J=3.00,5.70Hz,2H),3.06–3.25( m,2H),4.61(dd,J=5.02,8.57Hz,1H),5.08–5.25(m,2H),6.15(d,J=8.57Hz,1H),6.55( m,1H),7.33(dd,J=0.74,8.28Hz,1H),7.67(dd,J=2.53,8.20Hz,1H),8.35–8.43(m,1H).
[0062] Example 3
[0063] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-27):
[0064]
[0065] Its synthesis method is:
[0066] Add 2-thiophene methanol (1.2mmol, 137mg), BOC-Val-OH (1.5mmol, 325mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane to a round-bottom flask and stir evenly, then add EDCI (1.5mmol, 285mg). Stir the reaction at room temperature for 3h, and monitor the reaction by TLC. After the reaction is completed, add ethyl acetate (30mL), wash with water, saturated sodium bicarbonate and saturated brine in turn, and dry over anhydrous sodium sulfate. Filter and concentrate under reduced pressure to obtain intermediate 2, which is directly used in subsequent reactions without purification.
[0067] The intermediate 2 was transferred to a 25 mL round-bottom flask, and 4 mL of dichloromethane was added and placed in an ice bath. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel. After reacting for 2 h, the pH was adjusted to a weak alkaline (8-9) using saturated sodium carbonate. The mixed solution was extracted with dichloromethane (×20), the organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a colorless oily liquid or white solid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 nmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 nmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30 mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in sequence, and dried over anhydrous sodium sulfate. The residue was filtered off, concentrated under reduced pressure, and separated by column chromatography (eluent: DCM / MeOH=15 / 1) to obtain compound I-27.
[0068] Compound I-27 H NMR spectrum, 1H NMR(400MHz, CDCl3)δ0.89(dd,J=6.8,1.5Hz,3H),0.93(dd,J=6.7,1.5Hz,3H),2.13–2.03(m,1H),2.27–2.14(m,2H),2.36(s,3H),2.8 3(t,J=4.8Hz,2H),3.58(m,2H),4.33–4.24(m,1H),5.32–5.20(m,2H),6.76(m,1H),6.95(m,1H),7.02–6.98(m,1H)7.28–7.25(m,2H).
[0069] Example 4
[0070] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-31):
[0071]
[0072] Its synthesis method is:
[0073] 3-Phenoxybenzyl alcohol (1.2mmol, 240mg), BOC-Leu-OH (1.5mmol, 347mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane were added to a round-bottom flask and stirred evenly, and then EDCI (1.5mmol, 285mg) was added. The reaction was stirred at room temperature for 3h, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in turn, and dried over anhydrous sodium sulfate. Filtered and concentrated under reduced pressure to obtain intermediate 2, which was directly used in subsequent reactions without purification.
[0074] The intermediate 2 was transferred to a 25 mL round-bottom flask, and 4 mL of dichloromethane was added and placed in an ice bath. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel. After reacting for 2 h, the pH was adjusted to a weak alkaline (8-9) using saturated sodium carbonate. The mixed solution was extracted with dichloromethane (×20), the organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a colorless oily liquid or a white solid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30 mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in sequence, and dried over anhydrous sodium sulfate. The residue was filtered off, concentrated under reduced pressure, and separated by column chromatography (eluent: DCM / MeOH=15 / 1) to obtain compound I-31.
[0075] Compound I-31 H NMR spectrum, 1 H NMR(400MHz, CDCl3)δ0.85–0.98(m,6H),1.45–1.73(m,3H),2.28–2.36(m,2H),3.39(s,3H),2.44–2.54(m,2H),3.07–3.24(m ,2H),4.68–4.77(m,1H),5.06–5.20(m,2H),6.10(d,J=8.28Hz,1H),6.51–6.57(m,1H),6.93–7.13(m,6H),7.27–7.40(m,3H).
[0076] Example 5
[0077] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-36):
[0078]
[0079] Its synthesis method is:
[0080] 3,5-dichlorobenzyl alcohol (1.2mmol, 240mg), BOC-Ile-OH (1.5mmol, 347mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane were added to a round-bottom flask and stirred evenly, and then EDCI (1.5mmol, 285mg) was added. The reaction was stirred at room temperature for 3h, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in turn, and dried over anhydrous sodium sulfate. Filtered and concentrated under reduced pressure to obtain intermediate 2, which was directly used in subsequent reactions without purification.
[0081] The intermediate 2 was transferred to a 25 mL round-bottom flask, and 4 mL of dichloromethane was added and placed in an ice bath. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel. After reacting for 2 h, the pH was adjusted to a weak alkaline (8-9) using saturated sodium carbonate. The mixed solution was extracted with dichloromethane (×20), the organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a colorless oily liquid or a white solid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30 mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in sequence, and dried over anhydrous sodium sulfate. The residue was filtered, concentrated under reduced pressure, and separated by column chromatography (eluent: DCM / MeOH=15 / 1) to obtain compound I-36.
[0082] Compound I-36 H NMR spectrum, 1 H NMR(400MHz, CDCl3)δ0.75–0.91(m,6H),1.01–1.15(m,1H),1.24–1.40(m,1H),1.79–1.92(m,1H),2.20–2.28(m,2H),2.31(s,3H),2.36–2.46(m ,2H),2.98–3.16(m,2H),4.55–4.66(m,1H),4.92–5.11(m,2H),6.16(d, J=8.77Hz,1H),6.42–6.53(m,1H),7.12–7.17(m,2H),7.19–7.24(m,1H).
[0083] Example 6
[0084] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-56):
[0085]
[0086] Its synthesis method is:
[0087] Add 2-amino-4-trifluoromethylpyridine (1.2mmol, 195mg), BOC-Val-OH (1.5mmol, 325mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane into a round-bottom flask and stir evenly, then add EDCI (1.5mmol, 285mg). Stir the reaction at room temperature for 1h, and monitor the reaction by TLC. After the reaction is completed, add CH2Cl2 (20mL), wash with saturated sodium bicarbonate and saturated brine in turn, and dry over anhydrous magnesium sulfate. Filter and concentrate under reduced pressure to obtain a light yellow solid, which is directly used in subsequent reactions without purification.
[0088] The intermediate 2 was transferred to a 20 mL round-bottom flask and 4 mL of dichloromethane was added to dissolve. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel, and the reaction was stirred at room temperature. TLC was used to monitor the reaction. After the reaction was completed, it was transferred to a separatory funnel, 10 mL of water was added for extraction, and the water layer was collected and the pH was adjusted to alkaline (9-10) with saturated sodium carbonate, and then the water layer was extracted with dichloromethane (×30 mL), the organic phase was combined, washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain a light yellow oily liquid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, dichloromethane (20 mL) was added, and the mixture was washed with saturated sodium bicarbonate and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by column chromatography (eluent: dichloromethane: methanol = 15:1) to obtain the target compound I-56.
[0089] Compound I-56 hydrogen spectrum, 1H NMR(400MHz, CDCl3)δ9.44(d,J=46.6Hz,1H),8.58–8.53(m,1H),8.34(d,J=8.8Hz, 1H),7.92(dd,J=8.9,2.5Hz,1H),6.74–6.68(m,J=1.9Hz,1H),6.56–6.45(m,1H),4 .85–4.71(m,1H),3.37–3.15(m,2H),2.59–2.49(m,2H),2.44(s,3H),2.41–2.34(m ,2H),2.30–2.20(m,1H),1.04(dd,J=6.7,1.7Hz,3H),1.01(dd,J=6.8,1.7Hz,3H).
[0090] Example 7
[0091] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-61):
[0092]
[0093] Its synthesis method is:
[0094] 3-Phenoxyaniline (1.2mmol, 222mg), BOC-Val-OH (1.5mmol, 325mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane were added to a round-bottom flask and stirred evenly, and then EDCI (1.5mmol, 285mg) was added. The reaction was stirred at room temperature for 1h, and the reaction was monitored by TLC. After the reaction was completed, CH2Cl2 (20mL) was added, and the mixture was washed with saturated sodium bicarbonate and saturated brine in turn, and dried over anhydrous magnesium sulfate. Filtered and concentrated under reduced pressure to obtain a light yellow solid, which was directly used in subsequent reactions without purification.
[0095] The intermediate 2 was transferred to a 20 mL round-bottom flask and 4 mL of dichloromethane was added to dissolve. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel, and the reaction was stirred at room temperature. TLC was used to monitor the reaction. After the reaction was completed, it was transferred to a separatory funnel, 10 mL of water was added for extraction, and the water layer was collected and the pH was adjusted to alkaline (9-10) with saturated sodium carbonate, and then the water layer was extracted with dichloromethane (×30 mL), the organic phase was combined, washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain a light yellow oily liquid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, dichloromethane (20 mL) was added, and the mixture was washed with saturated sodium bicarbonate and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by column chromatography (eluent: dichloromethane: methanol = 15:1) to obtain the target compound I-61.
[0096] Compound I-61 hydrogen spectrum, 1 H NMR (400MHz, CDCl3) δ0.88 (dd, J=1.46, 6.58Hz, 3H), 0.92 (dd, J=1.46, 6.59Hz, 3H),2.05(m,1H),2.22(m,2H),2.35(s,3H),2.71–2.78(m,2H),3.58(m,2H),4. 39(m,1H),6.66–6.72(m,1H),6.76(m,1H),6.98–7.03(m,2H),7.10(m,1H),7.2 4–7.27(m,1H),7.27–7.30(m,2H),7.32–7.37(m,2H),8.01(m,1H),9.01(s,1H).
[0097] Example 8
[0098] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-65):
[0099]
[0100] Its synthesis method is:
[0101] 5-thiazolamine (1.2mmol, 120mg), BOC-Val-OH (1.5mmol, 325mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane were added to a round-bottom flask and stirred evenly, and then EDCI (1.5mmol, 285mg) was added. The reaction was stirred at room temperature for 1h, and the reaction was monitored by TLC. After the reaction was completed, CH2Cl2 (20mL) was added, and the mixture was washed with saturated sodium bicarbonate and saturated brine in turn, and dried over anhydrous magnesium sulfate. Filtered and concentrated under reduced pressure to obtain a light yellow solid, which was directly used in subsequent reactions without purification.
[0102] The intermediate 2 was transferred to a 20 mL round-bottom flask and 4 mL of dichloromethane was added to dissolve. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel, and the reaction was stirred at room temperature. TLC was used to monitor the reaction. After the reaction was completed, it was transferred to a separatory funnel, 10 mL of water was added for extraction, and the water layer was collected and the pH was adjusted to alkaline (9-10) with saturated sodium carbonate, and then the water layer was extracted with dichloromethane (×30 mL), the organic phase was combined, washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain a light yellow oily liquid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, dichloromethane (20 mL) was added, and the mixture was washed with saturated sodium bicarbonate and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by column chromatography (eluent: dichloromethane: methanol = 15:1) to obtain the target compound I-65.
[0103] Compound I-65 hydrogen NMR spectrum, 1 H NMR (400MHz, CDCl3) δ9.51(s,1H),8.33(d,J=1.8Hz,1H),8.13(d,J=1.8Hz,1H),8.01(m,1H),6.77(m,1H),4.54(m,1H),3.59(m,2H),2.84(m ,2H),2.36(s,3H),2.23(tdt,J=5.2,3.5,1.0Hz,2H),2.12–2.01(m,J=6.5Hz,1H),0.93(dd,J=6.6,1.5Hz,3H),0.89(dd,J=6.6,1.5Hz,3H).
[0104] Example 9
[0105] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-73):
[0106]
[0107] Its synthesis method is:
[0108] 2-amino-6-chloropyridine (1.2mmol, 154mg), BOC-Leu-OH (1.5mmol, 347mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane were added to a round-bottom flask and stirred evenly, and then EDCI (1.5mmol, 285mg) was added. The reaction was stirred at room temperature for 1h, and the reaction was monitored by TLC. After the reaction was completed, CH2Cl2 (20mL) was added, and the mixture was washed with saturated sodium bicarbonate and saturated brine in turn, and dried over anhydrous magnesium sulfate. Filtered and concentrated under reduced pressure to obtain a light yellow solid, which was directly used in subsequent reactions without purification.
[0109] The intermediate 2 was transferred to a 20 mL round-bottom flask and 4 mL of dichloromethane was added to dissolve. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel, and the reaction was stirred at room temperature. TLC was used to monitor the reaction. After the reaction was completed, it was transferred to a separatory funnel, 10 mL of water was added for extraction, and the water layer was collected and the pH was adjusted to alkaline (9-10) with saturated sodium carbonate, and then the water layer was extracted with dichloromethane (×30 mL), the organic phase was combined, washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain a light yellow oily liquid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, dichloromethane (20 mL) was added, and the mixture was washed with saturated sodium bicarbonate and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by column chromatography (eluent: dichloromethane: methanol = 15:1) to obtain the target compound I-73.
[0110] Compound I-73 hydrogen spectrum, 1 H NMR(400MHz, CDCl3)δ0.81–0.88(m,6H),1.41(m,1H),1.57(m,1H),1.68(m,1H),2.21(m,2H),2.34(s,3H),2.69–2.79(m,2H),3.5 6(q,J=0.99Hz,2H),4.39(m,1H),6.74(m,1H),7.23–7.27(m,1H),7.35(d,J=8.05Hz,1H),7.40(m,1H),7.67(m,1H),8.78(s,1H).
[0111] Example 10
[0112] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-79):
[0113]
[0114] Its synthesis method is:
[0115] Add 2-amino-3,5-dichloropyridine (1.2mmol, 196mg), BOC-Ile-OH (1.5mmol, 347mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane to a round-bottom flask and stir evenly, then add EDCI (1.5mmol, 285mg). Stir the reaction at room temperature for 1h, and monitor the reaction by TLC. After the reaction is completed, add CH2Cl2 (20mL), wash with saturated sodium bicarbonate and saturated brine in turn, and dry over anhydrous magnesium sulfate. Filter and concentrate under reduced pressure to obtain a light yellow solid, which can be directly used in subsequent reactions without purification.
[0116] The intermediate 2 was transferred to a 20 mL round-bottom flask and 4 mL of dichloromethane was added to dissolve. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel, and the reaction was stirred at room temperature. TLC was used to monitor the reaction. After the reaction was completed, it was transferred to a separatory funnel, 10 mL of water was added for extraction, and the water layer was collected and the pH was adjusted to alkaline (9-10) with saturated sodium carbonate, and then the water layer was extracted with dichloromethane (×30 mL), the organic phase was combined, washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain a light yellow oily liquid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, dichloromethane (20 mL) was added, and the mixture was washed with saturated sodium bicarbonate and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and separated by column chromatography (eluent: dichloromethane: methanol = 15:1) to obtain the target compound I-79.
[0117] Compound I-79 hydrogen spectrum, 1H NMR (400MHz, CDCl3) δ8.19 (s, 1H), 7.42 (m, 1H), 7.30 (d, J = 8.4Hz, 1H), 7.26 (s, 1H), 6.26 (m, 1H), 4.02 (m, 1H), 3.08 (q, J=0.96Hz,2H),2.35–2.13(m,2H),1.85(s,3H),1.72(m,2H),1.43(m,1H),1.01(m,1H),0.70(m,1H),0.33–0.40(m,6H).
[0118] Embodiment 11
[0119] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-91):
[0120]
[0121] Its synthesis method is:
[0122] Add 3,5-dichlorobenzyl alcohol (1.2mmol, 240mg), BOC-Ala-OH (1.2mmol, 107mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane to a round-bottom flask and stir evenly, then add EDCI (1.5mmol, 285mg). Stir the reaction at room temperature for 1h, and monitor the reaction by TLC. After the reaction is completed, add CH2Cl2 (20mL), wash with saturated sodium bicarbonate and saturated brine in turn, and dry over anhydrous magnesium sulfate. Filter and concentrate under reduced pressure to obtain a light yellow solid, which can be directly used in subsequent reactions without purification.
[0123] The intermediate 2 was transferred to a 25 mL round-bottom flask, and 4 mL of dichloromethane was added and placed in an ice bath. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel. After reacting for 2 h, the pH was adjusted to a weak alkaline (8-9) using saturated sodium carbonate. The mixed solution was extracted with dichloromethane (×20), the organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a colorless oily liquid or white solid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30 mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in sequence, and dried over anhydrous sodium sulfate. Filter with suction, concentrate under reduced pressure, and separate the intermediate by column chromatography (eluent: DCM / MeOH=15 / 1). Transfer the intermediate to a 20mL Schlenk reaction bottle, add 2-iodopropane (1mmol, 170mg) and anhydrous potassium carbonate (3mmol, 414mg) in sequence, add 5mL DMF and heat at 50°C for 2h, and monitor the reaction by TLC. After the reaction is completed, add ethyl acetate (30mL), wash with water, saturated sodium bicarbonate and saturated brine in sequence, and dry over anhydrous sodium sulfate. Filter with suction, concentrate under reduced pressure, and separate the target compound I-91 by column chromatography.
[0124] Compound I-91 hydrogen spectrum, 1 H NMR (400MHz, CDCl3) δ7.26(m,2H),7.22(m,1H),6.77–6.73(m,1H),5.27–5.17(m,2H),4.52(q,J=7.5Hz,1H),4.06–3.97(m, 1H), 3.50 (q, J = 1.1Hz, 2H), 2.77–2.73 (m, 2H), 2.17–2.12 (m, 2H), 1.36 (m, 3H), 1.31 (d, J = 7.0Hz, 3H), 1.20 (d, J = 7.0Hz, 3H).
[0125] Example 12
[0126] The structural formula of the arecoline derivative containing the amino acid fragment in this embodiment is shown in the following formula (I-104):
[0127]
[0128] Its synthesis method is:
[0129] 3-Phenoxybenzyl alcohol (1.2mmol, 240mg), BOC-Ala-OH (1.2mmol, 107mg), DMAP (0.5mmol, 61mg) and 5mL dichloromethane were added to a round-bottom flask and stirred evenly, and then EDCI (1.5mmol, 285mg) was added. The reaction was stirred at room temperature for 1h, and the reaction was monitored by TLC. After the reaction was completed, CH2Cl2 (20mL) was added, and the mixture was washed with saturated sodium bicarbonate and saturated brine in turn, and dried over anhydrous magnesium sulfate. Filtered and concentrated under reduced pressure to obtain a light yellow solid, which was directly used in subsequent reactions without purification.
[0130] The intermediate 2 was transferred to a 25 mL round-bottom flask, and 4 mL of dichloromethane was added and placed in an ice bath. Trifluoroacetic acid (2 mL) was slowly dripped into the round-bottom flask using a dropping funnel. After reacting for 2 h, the pH was adjusted to a weak alkaline (8-9) using saturated sodium carbonate. The mixed solution was extracted with dichloromethane (×20), the organic phase was combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a colorless oily liquid or white solid. The above product was transferred to a 25 mL reaction bottle, and arecaline (1 mmol, 141 mg), DMAP (0.5 mmol, 61 mg) and 5 mL of dichloromethane were added in sequence and stirred evenly, and then EDCI (2 mmol, 383 mg) was added. The reaction was stirred at room temperature overnight, and the reaction was monitored by TLC. After the reaction was completed, ethyl acetate (30 mL) was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated brine in sequence, and dried over anhydrous sodium sulfate. Filter with suction, concentrate under reduced pressure, and separate the intermediate by column chromatography (eluent: DCM / MeOH=15 / 1). Transfer the intermediate to a 20mL Schlenk reaction bottle, add bromocyclopropane (1mmol, 120mg) and anhydrous potassium carbonate (3mmol, 414mg) in sequence, add 5mL DMF and heat to 80℃ for 2h, and monitor the reaction by TLC. After the reaction is completed, add ethyl acetate (30mL), wash with water, saturated sodium bicarbonate and saturated brine in sequence, and dry over anhydrous sodium sulfate. Filter with suction, concentrate under reduced pressure, and separate the target compound I-104 by column chromatography.
[0131] Compound I-104 hydrogen spectrum, 1H NMR(400MHz, CDCl3)δ7.39–7.33(m,2H),7.26(d,J=15.8Hz,1H),7.15–7.10 (m,2H),7.04–7.01(m,2H),6.95–6.91(m,1H),6.85–6.82(m,1H),6.79–6.7 5(m,1H),5.23–5.11(m,2H),4.53(m,1H),3.52(m,2H),3.47–3.40(m,1H),2 .81–2.74(m,2H),2.19–2.12(m,2H),1.70–1.59(m,2H),1.43–1.36(m,5H).
[0132] The structures of some compounds (Ⅰ-1 to Ⅰ-106) after the structure of formula I is replaced by a substituent are shown in the following figure: Figure 1 As shown, other compounds described in the present invention can be prepared by the above method.
[0133] Application Examples
[0134] The antibacterial biological activity of the arecoline derivatives containing amino acid fragments prepared by the above steps of the present invention is determined as follows, and the determination experimental method adopts the mycelium growth rate method.
[0135] The tested fungi were Magnaporthe oryzae, Botryodipladia theobromae, Bipolaris cactivora, Bothryosphaeria dothidea, Colletotrichum musae, Fusarium verticillioides, Rhizoctonia solani, Sclerotinia sclerotiorum, and Phytophthora capsici, which were provided by the College of Tropical Agriculture and Forestry, Hainan University.
[0136] The test agent of the arecoline derivative containing amino acid fragments of the present invention is prepared into a liquid with a mass concentration of 100 mg / L. A 5 mm diameter puncher is used to take a bacterial cake, which is inoculated on a potato dextrose agar medium containing the test agent, and a medium containing the same solvent and auxiliary agent is used as a control. Each group is repeated three times, and the growth of the colony is observed. When the diameter of the blank control colony grows to 2 / 3 of the whole dish, the colony diameter is measured vertically and crosswise to calculate the antibacterial rate.
[0137] Result processing:
[0138] Bacterial inhibition rate (%) = [(average colony diameter of the control group - average colony diameter of the treatment group) / (average colony diameter of the control group - diameter of the bacterial cake)] × 100%
[0139] According to the inhibition rate of plant pathogenic fungi, it is divided into five levels: 90≤A≤100%; 80≤B<90%; 70≤C<80%; 60≤D<70%; E<60%.
[0140] The antibacterial activity test results of some compounds of the present invention are shown in Figure 2. It can be seen from the bioassay results in Figure 2 that the arecoline derivatives containing amino acid fragments provided by the present invention have good antibacterial activity against plant pathogenic fungi at a concentration of 100 mg / L. They can be used as active ingredients of chemical pesticides in the prevention and control of plant pathogens, and mixed with other carriers or adjuvants allowed in plant protection to prepare various dosage forms that can be used in agriculture.
[0141] In summary, the arecoline derivatives containing amino acid fragments provided by the present invention exhibit excellent inhibitory activity against agricultural plant pathogens, are suitable for the prevention and treatment of agricultural plant pathogens, and can be used for the development and use of active ingredients for the preparation of agricultural fungicides or adjuvants.
[0142] Obviously, the above-described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments, and are not intended to limit the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field should be included in the protection scope of the present invention.
Claims
1. An arecoline derivative containing an amino acid fragment, characterized in that: The general structural formula is formula (1), The X group represents O or NH; the value of n is 0, 1, 2 or 3.
2. An arecoline derivative containing an amino acid fragment according to claim 1, characterized in that: In formula (I), R 1 Selected from hydrogen atom, methyl, ethyl, cyclopropyl, isopropyl and tert-butyl.
3. An arecoline derivative containing an amino acid fragment according to claim 1, characterized in that: In formula (I), R 2 Selected from hydrogen atom, methyl, isopropyl, isobutyl, sec-butyl, benzyl and CH3SCH2CH2.
4. An arecoline derivative containing an amino acid fragment according to claim 1, characterized in that: In formula (I), R 3 is selected from aryl, aliphatic heterocycle, oxygen heterocycle, nitrogen heterocycle, sulfur heterocycle, aromatic heterocycle, benzoheterocycle, or condensed ring with a substituent, wherein R 3 The substituents are halogen atoms such as fluorine, chlorine and bromine, and mono- or poly-substituted groups such as methyl, isopropyl, tert-butyl, methoxy, nitro, cyano, trifluoromethoxy and trifluoromethyl.
5. An arecoline derivative containing an amino acid fragment according to claim 1, characterized in that: The preparation method of the compound is obtained by the following reaction steps.
6. Use of the arecoline derivative containing amino acid fragments according to any one of claims 1 to 4 as an agricultural fungicide.
7. The agricultural fungicide according to claim 6, characterized in that: The compound is used as an agricultural fungicide technical to prepare a preparation and a composition, wherein the agricultural fungicide contains at least one of the arecoline derivatives containing amino acid fragments as described in any one of claim 1.
8. The agricultural fungicide according to claim 6, characterized in that The formulation of the fungicide is at least one of emulsifiable concentrate, water emulsion, microemulsion, wettable powder, water dispersible granule, suspension or other suitable formulations.
9. The agricultural fungicide according to claim 6, characterized in that: The content of the arecoline derivative containing the amino acid fragment in the bactericidal composition prepared by the bactericidal agent is 1-99.9% by weight.
10. Use of the arecoline derivative or combination preparation containing amino acid fragments according to claims 1-4 and claims 7-9 as an agricultural fungicide, characterized in that: The agricultural fungicide is used for preventing and controlling plant pathogenic fungi diseases; wherein the plant pathogens include: Oomycetes, such as downy mildew, white rust, damping-off, cotton rot, phytophthora, and late blight; Basidiomycetes, such as stripe rust, smut, and sheath blight; Ascomycetes, such as powdery mildew, sclerotinia, black spot, and fusarium; Deuteromycetes, such as wilt, root rot, damping-off, anthracnose, verticillium wilt, gray mold, brown spot, black spot, black rot, stem rot, leaf spot, early blight, ring rot, leaf blight, and phomopsis.
Citation Information
Patent Citations
Nitrogenated heterocyclic compound and agricultural or horticultural bactericidal agent
CN103582633A
Pyridine compound and agricultural / horticultural bactericide
CN104470897A
Sterilizing compound and application thereof in pesticides
CN106719822A
A botanical fungicide and a preparing method thereof
CN107549212A
Plant-source antioxidant with attenuating effect on arecoline and screening method of plant-source antioxidant
CN116794282A
Cited By
Areca-arecoline hydrazide compound, preparation thereof and application of arecoline hydrazide compound in preparation of anti-inflammatory drugs
CN121895219A
A arecoline hydrazide compound and preparation and application thereof in preparation of anti-inflammatory drugs
CN121895219B
